PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2025	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Net Income	-7.07	30.66	0.33	-4.32	-4.24	-3.55
Asset Writedown & Restructuring Costs	-	-	2	-	-	-
Loss (Gain) From Sale of Investments	-6.6	-26.53	1.57	-	-	-
Stock-Based Compensation	0.26	0.48	0.67	0.65	0.11	0.44
Other Operating Activities	8.04	-8.94	-7.03	0.17	-	-0.08
Change in Accounts Payable	0.59	0.01	0.26	-0.24	0.03	-0.01
Change in Other Net Operating Assets	0.27	1.35	0.04	-0.05	-0.02	-0.13
Operating Cash Flow	-4.52	-2.98	-2.15	-3.79	-4.12	-3.33
Investment in Securities	-3	-7	-	-	-	-
Other Investing Activities	-	-	-5	-	-	-
Investing Cash Flow	-3	-7	-5	-	-	-
Long-Term Debt Repaid	-	-	-	-	-0.05	-0.06
Total Debt Repaid	-	-	-	-	-0.05	-0.06
Net Debt Issued (Repaid)	-	-	-	-	-0.05	-0.06
Issuance of Common Stock	-	-	0	0	87.36	4.7
Repurchase of Common Stock	-0.4	-2.54	-28.2	-13.56	-	-
Financing Cash Flow	2.09	-25.03	-10.71	-13.56	87.31	4.64
Foreign Exchange Rate Adjustments	-0	-0	-0	-0.01	0	0
Net Cash Flow	-5.43	-35.01	-17.86	-17.36	83.2	1.31
Cash Interest Paid	-	-	-	-	0	0
Cash Income Tax Paid	-	-	0	-	0	0
Levered Free Cash Flow	-7.51	-13.34	3.28	-3.52	-2.62	-1.97
Unlevered Free Cash Flow	-7.51	-13.34	3.28	-3.52	-2.62	-1.97
Change in Working Capital	0.85	1.36	0.3	-0.3	0.01	-0.15

Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q